Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
NM Kröger, JH Deeg, E Olavarria, D Niederwieser… - Leukemia, 2015 - nature.com
The aim of this work is to produce recommendations on the management of allogeneic stem
cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic …
cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic …
Advances in the study of chronic active Epstein-Barr virus infection: clinical features under the 2016 WHO classification and mechanisms of development
A Arai - Frontiers in pediatrics, 2019 - frontiersin.org
Chronic active Epstein-Barr virus infection (CAEBV) is one of the Epstein-Barr virus (EBV)-
positive T-or NK-lymphoproliferative diseases. It is considered rare and geographically …
positive T-or NK-lymphoproliferative diseases. It is considered rare and geographically …
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk …
evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk …
[HTML][HTML] Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib
provided significant improvements in splenomegaly, key symptoms, and quality-of-life …
provided significant improvements in splenomegaly, key symptoms, and quality-of-life …
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
N Kröger, T Giorgino, BL Scott… - Blood, The Journal …, 2015 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (SCT) is the only curative option for
patients with primary myelofibrosis (PMF), but information on its net advantage over …
patients with primary myelofibrosis (PMF), but information on its net advantage over …
[HTML][HTML] Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1/2 inhibitors
M Shanavas, U Popat, LC Michaelis, V Fauble… - Biology of Blood and …, 2016 - Elsevier
The impact of Janus kinase (JAK) 1/2 inhibitor therapy before allogeneic hematopoietic cell
transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this …
transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this …
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
D Rondelli, JD Goldberg, L Isola… - Blood, The Journal …, 2014 - ashpublications.org
Abstract From 2007 to 2011, 66 patients with primary myelofibrosis or myelofibrosis (MF)
preceded by essential thrombocythemia or polycythemia vera were enrolled into a …
preceded by essential thrombocythemia or polycythemia vera were enrolled into a …
Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies
RF Olsson, BR Logan, S Chaudhury, X Zhu, G Akpek… - Leukemia, 2015 - nature.com
Clinical outcomes after primary graft failure (PGF) remain poor. Here we present a large
retrospective analysis (n= 23 272) which investigates means to prevent PGF and early …
retrospective analysis (n= 23 272) which investigates means to prevent PGF and early …
[HTML][HTML] Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and …
We evaluated outcomes and associated prognostic factors in 233 patients undergoing
allogeneic hematopoietic cell transplantation (HCT) for primary myelofibrosis (MF) using …
allogeneic hematopoietic cell transplantation (HCT) for primary myelofibrosis (MF) using …
The role of cytokines in the initiation and progression of myelofibrosis
HC Hasselbalch - Cytokine & growth factor reviews, 2013 - Elsevier
Myelofibrosis (MF) is a life-threatening blood cancer characterized by progressive bone
marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms …
marrow fibrosis, splenomegaly, cytopenias, and debilitating constitutional symptoms …